Organicell Regenerative Medicine, Inc. announced on June 6, 2023, the board of directors appointed Harry Leider, M.D., M.B.A., as chief executive officer. Ian T. Bothwell, who has served as interim chief executive officer since November 2022, in addition to his position as chief financial officer will continue in his Chief Financial Officer role. Dr. Harry Leider, 65, has over 25 years of experience as a senior healthcare executive in a variety of innovative high growth healthcare companies.

Prior to joining Organicell, he served as the Chief Medical Officer and Executive Vice President of Apos Health from December 2022 to May 2023. From May 2018 to October 2022, Dr. Leider was the Chief Medical Officer and Executive Vice President of Gelesis, Inc., a biotech company that successfully developed an FDA-cleared therapy for obesity and went public in January 2022. Prior thereto, he served from 2013 to 2018 as the Chief Medical Officer and Group Vice President of Walgreens Boots Alliance.

He has also previously served as a member of the Boards of Directors of Alivio Therapeutics, TytoCare and Mobile Help. In addition, Dr. Leider has served on the faculty of Harvard Medical School and the John Hopkins Carey School of Business, where he taught healthcare marketing. He received his medical degree from the University of Pennsylvania, an M.B.A. from the University of Washington where he was a Robert Wood Johnson Clinical Scholar, and his B.A., summa cum laude from Pennsylvania State University.